Of course it is Shijiazhuang. North China Pharmaceutical and Shijiazhuang Pharmaceutical are the first and third in the national pharmaceutical industry. Do you need to say no?

North China Pharmaceutical Group Co., Ltd. is China's largest pharmaceutical company and is located in Shijiazhuang City, the capital of Hebei Province.

North China Pharmaceutical

The company's predecessor, North China Pharmaceutical Factory, was a key construction project during China's "First Five-Year Plan". Among the 156 key projects aided by the former Soviet Union, the antibiotic factory, It consists of a starch factory and a medicinal glass factory imported from the former Democratic Republic of Germany. Construction began in June 1953 with a total investment of 75.88 million yuan. It was fully put into operation in June 1958.

The establishment of the North China Pharmaceutical Factory ushered in the history of large-scale production of antibiotics in my country, ended China's dependence on imported penicillin and streptomycin, and significantly improved the situation of lack of medical treatment and medicine.

Over the past 50 years since its establishment, Huayao has operated steadily and gradually grown, its business scope has been broadened, sales have continued to grow, and its performance has remained excellent. Its main economic indicators have always been at the same level in the country. At the forefront of the industry, compared with when it was put into production, its business scope has expanded from simple pharmaceuticals to biology, chemicals, pesticides, commerce and other fields. The main products have increased from 5 to the current more than 430 varieties of various categories. It is a company with a single property rights structure. The factory has developed into an enterprise group with more than 30 subsidiaries and diversified investment entities.

CSPC Pharmaceutical Group Co., Ltd. was jointly established on August 21, 1997 by four companies including Hebei Pharmaceutical Group Company and Shijiazhuang First Pharmaceutical Group Company. It is the first company in the national pharmaceutical industry to A very large pharmaceutical company established through a strong alliance, it is also one of the large pillar enterprise groups in Hebei Province.

CSPC Pharmaceutical Group has total assets of 11.5 billion yuan and approximately 20,000 employees. It owns Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ouyi Pharmaceutical, Enbipu Pharmaceutical, Xinxin Pharmaceutical Hui Pharmaceutical and other more than ten subsidiaries are located in Hebei, Shanxi, Tianjin, Jilin, Liaoning and Inner Mongolia.

Among them, China National Pharmaceutical Group Co., Ltd., a holding subsidiary located in Hong Kong, is the first overseas listed company in the Chinese pharmaceutical industry. It is currently one of the largest pharmaceutical listed companies in Hong Kong and is also a component of the Hong Kong Hang Seng Red Chip Index. It has been named one of the 100 outstanding listed companies in Asia with a turnover of less than US$1 billion for two consecutive times by the world-famous "Forbes" magazine.

In July 2009, China Pharmaceutical was listed in the "First Top 20 Most Competitive Pharmaceutical Listed Companies in China" list.

CSPC Pharmaceutical Group is a large pharmaceutical enterprise integrating science, industry and trade. It is mainly engaged in the development, production and sales of pharmaceutical products.

The products mainly include nearly a thousand varieties in six series including antibiotics, vitamins, cardiovascular and cerebrovascular, antipyretic and analgesic, digestive system drugs and respiratory system drugs. Penicillin series and vitamin series are the leading products.

At present, the annual production capacity of vitamin C has reached 35,000 tons, the annual production capacity of penicillin series APIs has reached 16,000 tons, the production scale of 7-ACA has reached 1,600 tons/year, and the annual production capacity of amoxicillin It has reached 6,000 tons, and its annual caffeine production capacity has reached 8,000 tons, ranking first in the world.

CSPC Pharmaceutical Group’s annual production capacity of pharmaceutical products is 3 billion injection powders, 20 billion tablets, 8 billion capsules, and 1 billion soft capsules.

The output, scale and strength of CSPC’s leading products are among the best in the country, and it has developed into one of the largest “chemical raw material pharmaceutical production bases” and “comprehensive preparation production bases” in China.

Currently, CSPC Pharmaceutical Group has 30 product varieties with sales exceeding 100 million yuan, and its products are sold throughout the country and more than 60 countries and regions around the world.

Since its establishment more than ten years ago, CSPC Pharmaceutical Group has continued to innovate and forge ahead, achieved leap-forward development, and achieved gratifying results. It has successively won the title of National Advanced Group in the Pharmaceutical System, Advanced Enterprise in Quality and Efficiency, and Product Honorary titles such as Quality Assurance Commitment Unit, National May Day Labor Certificate, and China Environmental Protection Enterprise Love Award.

In 2009, CSPC Pharmaceutical Group achieved tax-excluding sales revenue of 10.6 billion yuan, profits and taxes of 1.46 billion yuan and 1.21 billion yuan respectively, and paid various taxes of 500 million yuan.

The entire group achieved direct export earnings of US$450 million, ranking at the forefront of Chinese pharmaceutical manufacturing companies.

In terms of scientific research and development, CSPC Pharmaceutical Group relies on the company's "Postdoctoral Research Workstation", national enterprise technology center, "863 Plan" high-tech industrialization base and Hebei Provincial Preparation Engineering Technology Center. In recent years, It has developed more than 90 national new drugs, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields.

Currently, CSPC Pharmaceutical Group has applied for more than 220 patents, 116 of which have been authorized, and applied for 17 PCT international patents.

Among them, "Enbipu", a national first-class new drug with independent intellectual property rights, is the world's leading drug in the field of stroke treatment. It is the third national first-class new drug with independent intellectual property rights in my country, filling the gap. Hebei Province has a history of being a national first-class new drug and is protected by patents in 86 countries around the world.

At present, the company has signed a patent transfer agreement with two well-known companies in the United States and South Korea for Enbipu soft capsules in the European, American and Korean markets, pioneering the transfer of Chinese pharmaceutical companies to the most developed countries in the world. The precedent of pharmaceutical intellectual property rights has won honor for the country and nation.

In 2008, under the leadership of the Ministry of Science and Technology, we took the lead in organizing and establishing the China Antibiotic Industry Technology Innovation Alliance, and received project support from the National Science and Technology Support Plan.

In the national major science and technology application for "Major New Drug Creation", 1 innovative drug incubation base, 3 innovative drug research and development technology platforms and 6 new drug development projects were settled in CSPC, which has become a policy in the industry. Enterprises with the most project support.

In terms of product quality, CSPC Pharmaceutical Group has established a complete three-level quality management system. All drugs have passed GMP certification. All subsidiaries have passed ISO9000, OHSAS18000 and ISO14001 certification, and the products have passed the market inspection. The rate always remains 100.

At the same time, the company uses technology to improve quality connotation. Currently, 8 API products such as caffeine, vitamin C, VB12, and amoxicillin have obtained EU COS certification, and have obtained the "qualification to enter the European and American high-end pharmaceutical markets." pass".

In terms of brand building, CSPC Group owns two "China Famous Trademarks": "CSPC" and "OUYI". According to the evaluation of the World Brand Laboratory, one of the world's top five brand value assessment agencies, "CSPC "The brand has been selected into the "China's 500 Most Valuable Brands" for four consecutive times since 2005; CSPC Pharmaceutical Group has been among the top 500 Chinese companies for three consecutive times, and was shortlisted for the 2008 China's Most Valuable Brand Enterprise Award. It is the 2008 China Chemical Pharmaceutical API Manufacturing Industry A pioneering enterprise.

Looking into the future, CSPC people will continue to adhere to the corporate philosophy of "making good medicine for China", devote themselves to human health, and contribute to society with more, newer, and better medicines. , and strive to build CSPC into a first-class modern large-scale pharmaceutical company in China and a Fortune 500 company in the world.